Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study-Reference-Cited by-同舟云学术

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study

Published:2015-05 Issue:5 Volume:26 Page:914-920
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Monk B.J.,Ghatage P.,Parekh T.,Henitz E.,Knoblauch R.,Matos-Pita A.S.,Nieto A.,Park Y.C.,Cheng P.S.,Li W.,Favis R.,Ricci D.,Poveda A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/5/914/19446346/mdv071.pdf

Reference17 articles.

1. Global cancer statistics, 2002;Parkin;CA Cancer J Clin,2005

2. Patient-derived breast tumor xenografts facilitating personalized cancer therapy;Landis;Breast Cancer Res,2013

3. Product monograph [database on the Internet] 2010. http://hemonc.org/docs/packageinsert/trabectedin.pdf (10 December 2014, date last accessed).

4. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production;Allavena;Cancer Res,2005

5. Role of macrophage targeting in the antitumor activity of trabectedin;Germano;Cancer Cell,2013

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?;Drug Design, Development and Therapy;2024-06

2. Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial;Journal of Clinical Oncology;2024-05-01

3. Synergetic approaches of fucoidan and trabectedin complex coated PLGA nanoparticles effectively suppresses proliferation and induce apoptosis for the treatment on non-small cell lung cancer;Journal of Biomaterials Science, Polymer Edition;2024-03-26

4. The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis;Critical Reviews in Oncology/Hematology;2024-01

5. Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs;Cancer Research Communications;2023-08-25